mRNA

#mRNA #mRNA-based vaccines #Promega #Therapeutics

Bridge innovation to implementation with high-quality RNA therapeutic raw materials 

This article is sponsored by Promega. In today’s fast-paced RNA therapeutic development landscape, experience matters. With over 40 years of experience in RNA synthesis by in vitro transcription (IVT), Promega smooths the transition from research to production by reducing risk and saving time, without compromising the quality of RNA synthesis… Read More

#News

#Genetics / genomics #mRNA #Rare disease #RNA

How mRNA’s tiny cousin could treat thousands of rare diseases

DDW Editor Reece Armstrong speaks to Dr Caroline Kӧhrer, Vice President, Discovery Platform, Alltrna, about the biology behind tRNAs and how they could help produce a medicine that could treat thousands of rare diseases that share the same genetic mutation. RA: Why are tRNA molecules so important for rare genetic… Read More

#Exclusive Content

#BioNTech #Cancer immunotherapy #Cancer vaccine #European Commission #Immunology / Virology & Vaccines #mRNA #University College London Hospitals

First patient dosed in UK novel cancer vaccine trial

A lung cancer patient at University College London Hospitals (UCLH) is the first to receive a novel cancer vaccine designed to prime the immune system to recognise and fight cancer cells.  It is the first time this immunotherapy made by BioNTech will be studied in a clinical… Read More

#Cancer Research #News

Lipid nanoparticle mRNA vaccine
#Drug delivery #Guide #Lipid based nanoparticle (LNP) #mRNA #RNA Therapeutics #siRNA

Lipid nanoparticle formulation: Download the Guide

A new Guide is now available for free download from Cayman Chemical entitled ‘Lipid Nanoparticle Formulation: Basic Concepts & Preparation Procedures‘. Lipid nanoparticles (LNPs) have great potential to revolutionise the development of nucleic acid therapies. Download the Guide to learn more about: The basic concepts and components… Read More

#News

#Drug delivery #Lipid based nanoparticle (LNP) #mRNA #RNA Therapeutics #siRNA

Lipid Nanoparticle Formulation: Basic Concepts & Preparation Procedures

Lipid nanoparticles (LNPs) have great potential to revolutionise the development of nucleic acid therapies. Download the Guide to learn more about: The basic concepts and components of lipid-based drug delivery systems Important considerations for LNP design, stability, and storage Techniques for LNP preparation, characterisation, and functional assessment… Read More

#Intelligence #Resources

GBP pound sterling funding
#Biopharmaceuticals #Biotechnology #Finance #Investment #mRNA #Novo Holdings #Oxford Nanopore Technologies

Investing in a new generation of molecular analysis technology 

Novo Holdings has announced a £5 million investment in Oxford Nanopore Technologies as part of an equity issue and intends to add to this investment over time, with further purchases in the secondary market, subject to availability and price (among other factors).  Oxford Nanopore has developed a new generation of… Read More

#Business & Investment #News

Vaccine production
#Cancer vaccine #mRNA #mRNA-based vaccines #Oncology #Personalised medicine #University of Queensland

Personalised cancer vaccines to be produced at Queensland lab

A new facility at The University of Queensland, Australia, will provide researchers with cancer vaccines tailored to individual patients. The lab at UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) will bring together the equipment and expertise to enable the design, manufacture and delivery of new… Read More

#News

RNA vaccine
#Drug discovery #mRNA #RNA Therapeutics #Vaccines

The evolution of the RNA therapeutics landscape 

Bruce Sullenger, PhD Founder and Scientific Advisor of Basking Biosciences, and Joseph W And Dorothy W Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University, explores the rise of RNA therapeutics.   For decades, the life sciences community held the belief… Read More

#Exclusive Content

RNA
#Circio Holding #circular RNAs #Gene therapy #Genetic diseases #In vivo #mRNA

How does circVec technology compare to conventional mRNA? 

Circio has announced updated in vivo data that demonstrates a substantial durability advantage of Circio’s circVec technology over conventional mRNA expression. In addition, Circio has undertaken sequence optimisation resulting in a new circVec 2.2 design.   “The circVec 2.1 design is performing very well in… Read More

#News

#Exsilio Therapeutics #Financing #Genetics / genomics #mRNA #Start-ups

mRNA-based drug company launches with $82 million

Genomic medicine developer Exsilio Therapeutics has emerged from stealth with $82 million in Series A financing. The funding was co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, JP Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight. Exsilio… Read More

#Business & Investment #News #Start-up Zone

#FDA #Immunology / Virology & Vaccines #Moderna #mRNA #mRNA-based vaccines #Respiratory syncytial virus

US approves first mRNA vaccine since Covid-19

The US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA… Read More

#News #Regulatory

Vaccine
#BioNTech #Cancer vaccine #Clinical trials #mRNA #Oncology #UK

NHS England launches country-wide cancer vaccine trials

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments. The vaccines being jointly developed by biopharmaceutical companies BioNTech and Genentech are… Read More

#Cancer Research #News #Trending News

CRISPR gene editing
#Caszyme #CRISPR #CRISPR-Cas9 #mRNA

CRISPR company adds mRNA synthesis to offering

Lithuanian CRISPR gene editing company Caszyme has added early-stage mRNA synthesis, analysis, and optimisation to its range of offerings. The strategic development was announced at BIO2024 in San Diego, US. Caszyme CEO Dr Monika Paulė comments: “The demand for tailored gene editing solutions continues… Read More

#News

#Bone disease #Collaboration #Heart disease #mRNA #Oncology #Partnership

This week in drug discovery (20-24 May) 

News round-up for 20-24 May by DDW Senior Digital Content Editor Diana Spencer. The headline news this week emphasises the importance of shared expertise and collaboration, whether that be between nations, companies or research institutions, to enable the greatest advances in drug discovery. The top stories:… Read More

#News

#Autoimmune disease #Collaboration #etherna #Hasselt University #Lipid based nanoparticle (LNP) #mRNA

Autoimmune mRNA therapeutics research collaboration 

etherna has entered a research collaboration with Hasselt University (UHasselt) to develop an mRNA based treatment for autoimmune disorders.   Funded by Flanders Innovation & Entrepreneurship (VLAIO), the project aims to combine etherna’s vast expertise in developing customised mRNA and lipid-based nanoparticle technologies for immuno-modulation with UHasselt’s research into autoimmune diseases… Read More

#Business & Investment #News